Evidence reference only. Not medical advice, not a dosing guide, and not a recommendation to use any drug.
Echo The Echo Compendium
<- All drugs
Investigational and unapproved. Findings below describe what trials and reports have observed. Nothing here is an endorsement, a claim of safety or effectiveness, or a clinical recommendation.

BI 3034701

INVESTIGATIONAL

GLP-1, GIP and neuropeptide Y2 receptor triple agonist

3
graded results
0
ongoing records
2
effect domains
Evidence spread
High evidence 0Moderate evidence 0Low evidence 0Very low evidence 3

BI 3034701 is investigational in the scoped programme below. Study records do not establish approval, safety or personal suitability. Results describe observations and do not provide treatment advice.

Dated status sources

INVESTIGATIONAL Global programme; Obesity; Subcutaneous injection; as of 2026-07-13. ClinicalTrials.gov

The grade rates how strong the evidence is, not how good or safe the drug is. A low or very-low grade means the evidence is thin, not that an effect is harmful or ruled out.

Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
BI 3034701 INVESTIGATIONAL
weight-loss Decrease
Very low evidence

BI 3034701 (Boehringer Ingelheim / Gubra) is an investigational, potential first-in-class triple GLP-1 / GIP / NPY2 receptor agonist peptide for obesity. The phase 1...

Boehringer Ingelheim / Gubra press releases (phase 1 start 2024; phase 2 advance 2026) Source
Full findingBI 3034701 (Boehringer Ingelheim / Gubra) is an investigational, potential first-in-class triple GLP-1 / GIP / NPY2 receptor agonist peptide for obesity. The phase 1 first-in-human trial demonstrated a favourable safety/tolerability profile and showed encouraging weight loss; Boehringer plans to initiate phase 2 in mid-2026.
PopulationPhase 1 (NCT06352437): randomised first-in-human placebo-controlled, two parts - Part A healthy men 18-55; Part B adults 18-65 with overweight/obesity otherwise healthy; ~124 participants; completed H2 2025
Fundingindustry (company press release on own pipeline)
Comparatorsplacebo
BI 3034701 INVESTIGATIONAL
weight-loss Not directional
Very low evidence

No human weight-loss data reported; rationale is multi-pathway satiety/body-weight regulation.

Boehringer Ingelheim / Gubra press disclosures, 2025-2026. Source
PopulationNone (preclinical/early clinical)
Fundingindustry (company press release on own pipeline)
Thin or bounded evidence here means uncertainty remains visible. It is not evidence that an effect has been ruled out.
BI 3034701 INVESTIGATIONAL
pharmacology Not directional
Very low evidence

Mechanism verified: investigational, potential first-in-class triple agonist at GLP-1, GIP and NPY2 (Y2) receptors, designed to engage multiple satiety pathways.

Gubra / Boehringer Ingelheim announcement: Boehringer Ingelheim advances Gubra-originated... Source
PopulationPreclinical/early development (mechanism per company/partner disclosures)
Fundingindustry - Boehringer Ingelheim (trial sponsor; inferred from registration trial)